[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522708":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":25,"centralContacts":32,"locations":40,"responsibleParty":86,"collaborators":89,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":10,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":10,"enrollmentInfo":101,"targetDuration":104,"studyType":105,"phases":10,"briefSummary":106,"conditions":107,"keywords":10,"overallStatus":62,"whyStopped":10,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"University of Bologna","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Breast cancer",null,"Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs.\n\n(Non-interventional prospective patient registry)",[13],"Combination Product: Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy",{"label":15,"type":10,"description":16,"interventionNames":10},"Female and Male","Diagnosis of cancer scheduled for treatment according to the treating physician's discretion.\n\n(Non-interventional patient registry)",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"COMBINATION_PRODUCT","Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy","Follow-up visits at baseline, 3-months, and 1-year",[9],[24],"Non-interventional patient registry",[26,29],{"name":27,"affiliation":5,"role":28},"Prof. Olivia Manfrini, MD","PRINCIPAL_INVESTIGATOR",{"name":30,"affiliation":31,"role":28},"Prof. Giuseppina Novo, MD","Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Edina Cenko","CONTACT","+3905121444911","dimec.epicardio@unibo.it",{"name":39,"role":35,"phone":36,"phoneExt":10,"email":37},"Maria Bergami",[41,52,60,71,81],{"facility":5,"status":42,"city":43,"state":10,"zip":10,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":10},"NOT_YET_RECRUITING","Bologna","Italy","IT",{"type":47,"coordinates":48},"Point",[49,50],11.33875,44.49381,{"lat":50,"lon":49},{"facility":53,"status":42,"city":54,"state":10,"zip":10,"country":44,"countryCode":45,"cosmosGeoPoint":55,"geoPoint":59,"contacts":10},"Azienda Ospedaliera Universitaria Policlinico \"Paolo Giaccone\"","Palermo",{"type":47,"coordinates":56},[57,58],13.3636,38.1166,{"lat":58,"lon":57},{"facility":61,"status":62,"city":63,"state":10,"zip":10,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":70,"contacts":10},"Ss. Cyril and Methodius University in Skopje, University Clinic","RECRUITING","Skopje","North Macedonia","MK",{"type":47,"coordinates":67},[68,69],21.43141,41.99646,{"lat":69,"lon":68},{"facility":72,"status":62,"city":73,"state":10,"zip":10,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":80,"contacts":10},"University of Belgrade, Clinical Center of Serbia","Belgrade","Serbia","RS",{"type":47,"coordinates":77},[78,79],20.46513,44.80401,{"lat":79,"lon":78},{"facility":82,"status":62,"city":73,"state":10,"zip":10,"country":74,"countryCode":75,"cosmosGeoPoint":83,"geoPoint":85,"contacts":10},"University of Belgrade, Clinical Hospital Center Bezanijska kosa",{"type":47,"coordinates":84},[78,79],{"lat":79,"lon":78},{"type":28,"investigatorFullName":87,"investigatorTitle":88,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Olivia Manfrini, MD","Professor",[90],{"name":91,"class":6},"Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo","100522708","detection-and-prevention-of-cancer-related-cardiovascular-toxicity-registry-100522708",false,"NCT06086132","Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry","Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry (ISACS CARDIONCO-PREDICT)","Inclusion Criteria:\n\n* Age 18 years old or older\n* Capable of giving informed consent\n* Diagnosis of cancer scheduled for treatment according to treating physician's discretion\n* Life expectancy \\>1 year\n* For the prospective validation of HFA-ICOS risk score validation: Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old\n* Not able to give informed consent\n* Life expectancy \\\u003C1 year\n* Advanced-stage cancer not eligible for treatment (subjects with an indication of palliative care) according to treating physician's","ALL","18 Years",{"count":102,"type":103},10000,"ESTIMATED","3 Years","OBSERVATIONAL","This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of cancer therapy-related cardiovascular toxicity and cancer therapy-related cardiac dysfunction",[108],"Cancer Related Cardiovascular Toxicity","2025-06-16",{"date":111,"type":112},"2025-06-19","ACTUAL",{"date":114,"type":112},"2025-05-01",{"date":116,"type":103},"2026-12-31",{"name":5,"class":6},5]